A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

NCT06826768 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: REGN5678
DRUG: Cemiplimab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]